ASCO 2023 | How can PD-1 inhibition be enhanced in glioblastoma?

As a result of the hostile tumor microenvironment, immune checkpoint inhibitor monotherapy has typically been ineffective in glioblastoma, which as also been regarded as immunologically cold. Stephen Joseph Bagley, MD, MSCE, Hospital of the University of Pennsylvania, Philadelphia, PA, discusses strategies to improve the efficacy of immune checkpoint inhibitors in patients with glioblastoma. By adding radiotherapy and GITR inhibition, the tumor can be primed for immunotherapy and regulatory T cell activity can be reduced. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.